Search

Your search keyword '"Isoxazoles chemistry"' showing total 1,516 results

Search Constraints

Start Over You searched for: Descriptor "Isoxazoles chemistry" Remove constraint Descriptor: "Isoxazoles chemistry"
1,516 results on '"Isoxazoles chemistry"'

Search Results

251. Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.

252. Aminobenzisoxazole compounds as agonists of α7 nicotinic acetylcholine receptors: a patent evaluation (WO 2017027600).

253. Synthesis of novel isoxazoline-containing podophyllotoxin/2'(2',6')-(di)halogenopodophyllotoxin derivatives and their insecticidal/acaricidal activities.

254. 3D-QSAR, molecular docking, and molecular dynamic simulations for prediction of new Hsp90 inhibitors based on isoxazole scaffold.

255. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.

256. Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).

257. Palladium-Catalyzed Asymmetric Allylic Alkylation of 4-Substituted Isoxazolidin-5-ones: Straightforward Access to β 2,2 -Amino Acids.

258. Brain Vacuolation Resulting From Administration of the Type II Ampakine CX717 Is An Artifact Related to Molecular Structure and Chemical Reaction With Tissue Fixative Agents.

259. Integrated metabolic models for xenobiotic induced mitochondrial toxicity in skeletal muscle.

260. Formulation and Characterization of Fast-Dissolving Sublingual Film of Iloperidone Using Box-Behnken Design for Enhancement of Oral Bioavailability.

261. Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activity.

262. Regioselective synthesis of 3,4-diaryl-5-unsubstituted isoxazoles, analogues of natural cytostatic combretastatin A4.

263. Isoxazole-containing neonicotinoids: Design, synthesis, and insecticidal evaluation.

264. Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold.

265. Structure based virtual screening of the Ebola virus trimeric glycoprotein using consensus scoring.

266. Molecular modeling studies of pseudouridine isoxazolidinyl nucleoside analogues as potential inhibitors of the pseudouridine 5'-monophosphate glycosidase.

267. Design, Synthesis and Anti-breast Cancer Activity of Some Novel Substituted Isoxazoles as Anti-breast Cancer Agent.

268. Green approach for the synthesis of thiophenyl pyrazoles and isoxazoles by adopting 1,3-dipolar cycloaddition methodology and their antimicrobial activity.

269. Binding free energy predictions of farnesoid X receptor (FXR) agonists using a linear interaction energy (LIE) approach with reliability estimation: application to the D3R Grand Challenge 2.

270. CDOCKER and λ-dynamics for prospective prediction in D₃R Grand Challenge 2.

271. DNA intercalators based on (1,10-phenanthrolin-2-yl)isoxazolidin-5-yl core with better growth inhibition and selectivity than cisplatin upon head and neck squamous cells carcinoma.

272. Targeting Akt as strategy to kill cancer cells using 3-substituted 5-anilinobenzo[c]isoxazolequinones: A preliminary study.

273. Lessons learned in induced fit docking and metadynamics in the Drug Design Data Resource Grand Challenge 2.

274. Synthesis of New Isoxazole-, Pyridazine-, Pyrimidopyrazines and Their Anti-Inflammatory and Analgesic Activity.

275. A cross docking pipeline for improving pose prediction and virtual screening performance.

276. Using physics-based pose predictions and free energy perturbation calculations to predict binding poses and relative binding affinities for FXR ligands in the D3R Grand Challenge 2.

277. Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations.

278. Screening of curcumin-derived isoxazole, pyrazoles, and pyrimidines for their anti-inflammatory, antinociceptive, and cyclooxygenase-2 inhibition.

279. Optimal affinity ranking for automated virtual screening validated in prospective D3R grand challenges.

280. Isoxazol-5(2H)-one: a new scaffold for potent human neutrophil elastase (HNE) inhibitors.

281. Effect of mofezolac-galactose distance in conjugates targeting cyclooxygenase (COX)-1 and CNS GLUT-1 carrier.

282. Functional reconstitution of cell-free synthesized purified K v channels.

283. Absolute configuration assignment of (+)-fluralaner using vibrational circular dichroism.

284. Through scaffold modification to 3,5-diaryl-4,5-dihydroisoxazoles: new potent and selective inhibitors of monoamine oxidase B.

285. Farnesoid X receptor regulates SULT1E1 expression through inhibition of PGC1α binding to HNF4α.

286. LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma.

287. Design, Synthesis and Bioactivities of Novel Isoxazole-Containing Pyrazole Oxime Derivatives.

288. Nitroisoxazolones Showing Diverse Chemical Behavior: A Use ful Building Block for Polyfunctionalized Systems.

289. The position of fluorine in CP-118,954 affects AChE inhibition potency and PET imaging quantification for AChE expression in the rat brain.

290. Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes.

291. Regiospecific Synthesis of Ring A Fused Withaferin A Isoxazoline Analogues: Induction of Premature Senescence by W-2b in Proliferating Cancer Cells.

292. Diverting Reactive Intermediates Toward Unusual Chemistry: Unexpected Anthranil Products from Davis-Beirut Reaction.

293. Constructing novel dihydrofuran and dihydroisoxazole analogues of isocombretastatin-4 as tubulin polymerization inhibitors through [3+2] reactions.

294. DNA incision evaluation, binding investigation and biocidal screening of Cu(II), Ni(II) and Co(II) complexes with isoxazole Schiff bases.

295. Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6).

296. Discovery of Small Molecules Targeting the Synergy of Cardiac Transcription Factors GATA4 and NKX2-5.

297. ML327 induces apoptosis and sensitizes Ewing sarcoma cells to TNF-related apoptosis-inducing ligand.

298. Synthesis of novel forskolin isoxazole derivatives with potent anti-cancer activity against breast cancer cell lines.

299. Isoxazole ring as a useful scaffold in a search for new therapeutic agents.

300. Identification of α7 Nicotinic Acetylcholine Receptor Silent Agonists Based on the Spirocyclic Quinuclidine-Δ 2 -Isoxazoline Scaffold: Synthesis and Electrophysiological Evaluation.

Catalog

Books, media, physical & digital resources